Fennec Pharmaceuticals (FENC) CEO Hackman received 1,159 shares
CEO Jeffrey Hackman received 1,159 shares released from restriction, bringing direct holdings to 70,844 units.
Insider transactions reported
Jeffrey S. Hackman (Chief Executive Officer at Fennec Pharmaceuticals Inc., FENC) reported that they received 1,159 shares on Oct 31, 2026. After these transactions the filing shows 70,844 shares held directly.
- Reporting person
- Hackman Jeffrey S.
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 31, 2026 | Grant or award (A) | Common Shares1 | +1,159 | - | - | 70,844 direct |
Holdings before and after
- Common Shares: 69,685 to 70,844 direct
Footnotes from the filing
- 1. Represents shares released from restriction from shares awarded 3/28/2025.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Hackman report in this FENC Form 4?
Jeffrey S. Hackman (Chief Executive Officer at Fennec Pharmaceuticals Inc., FENC) reported that they received 1,159 shares on Oct 31, 2026. After these transactions the filing shows 70,844 shares held directly.
How many FENC shares does Hackman hold after this filing?
The filing shows 70,844 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for FENC
Across the 26 sessions after earlier FENC headlines, the stock closed higher 15 times and lower 10 times, with a median move of 2.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | FENC | SPY |
|---|---|---|---|
| Sep 17, 2026 | Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 | +2.2% | +1.1% |
| Aug 11, 2026 | Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update | +16.8% | -0.3% |
| Aug 5, 2026 | Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 | +4.1% | -0.2% |
| Jun 15, 2026 | Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | +2.1% | +1.8% |
| Jun 11, 2026 | Fennec Announces Results of Annual Meeting | +1.7% | +1.7% |
| May 22, 2026 | Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | -0.4% | +0.4% |
Earlier insider filings at FENC
- Nov 2, 2026Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.54% to 28,902 units (SEC Form 4)
- Nov 2, 2026CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.69% to 248,558 units (SEC Form 4)
- Oct 13, 2026SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- Oct 13, 2026SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- Oct 13, 2026SEC Form 4 filed by Fennec Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Follow FENC and get a push notification the moment its next story breaks.